Fc-Fusion Proteins are also called Fc chimeric proteins or Fc-Ig based chimeric fusion proteins, also called Fc-tag proteins. Fc-Fusion Protein is the compositional Fc domain of IgG that is genetically bound to a peptide/protein of interest. Fc-Fusion Proteins are gaining importance in in vivo and in vitro studies. Fc fusion proteins can range from single peptides, ligands that activate upon binding to cellular receptors, signaling molecules, extracellular domains of receptors, and bait proteins that identify binding partners for protein microarrays.
One of the key features of Fc-fusion proteins in vivo is that they can prolong the plasma half-life of the desired protein. This function of Fc-Fusion Protein enhances the therapeutic effect of biological agents. Fc-Fusion Proteins are now routinely used in non-clinical applications such as immunohistochemistry, protein arrays, and flow cytometry. In these applications, the FC region is stable and folds independently to allow other different types of proteins to attach and maintain function.
Get Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/16414
Market segmentation:
Based on the application
- In vitro
- Immunohistochemistry
- Flow cytometry
- Binding assay
- Microarray technology
- in vivo
- Biotherapeutic drug
Based on end user
- Hospital and ASC
- Ophthalmology or eye formation clinic
based on region
- North America
- Europe
- Asia Pacific
- latin america
- Middle East and Africa
Request a table of contents here for a complete list of market players @ https://www.persistencemarketresearch.com/toc/16414
There are many Fc fusion proteins in clinical trials, many in various stages of preclinical development. Fc fusion proteins and monoclonal antibodies account for a combined 43% of all therapeutic protein markets. Many Fc-Fusion proteins are still in the pipeline, indicating that the market for Fc-Fusion proteins is likely to rise during the 2016-2024 forecast period.
From research and global sales, the most successful Fc fusion protein was etanercept, which surpassed the most successful therapeutic antibody, bevacizumab. The market for the Fc fusion protein market is similar to the biologics, pharmaceutical, and biotechnology markets.
From a global perspective, North America holds the largest market share of Fc fusion proteins due to the increased effectiveness of Fc fusion protein therapies and the adoption rate of advanced Fc fusion proteins. The high adoption rate of Fc fusion proteins in North America will probably help the region maintain its position as a major region in the projected years.
Book Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/16414
Today, the global Fc fusion protein market is highly competitive due to the involvement of many established players. Leading companies in the global Fc fusion protein market include Astellas Pharma US, Regeneron, Amgen, Ligand Pharmaceuticals, Bristol Myers Squibb, Viventia and Genzyme.
About Us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States United
States Ph.D. – +1-646-568-7751
US-Canada Toll Free – +1 800-961-0353
Japan Office: 1-2-1 Kinshi Arca Central Building
14 / F Tokyo, 130-0013, Japan
Tel 1-888-863-3700
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com